Protocol
11-088
Full Title
A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects with Metastatic Melanoma
Purpose
MORAb-004 is an investigational drug that binds to the surface of some cancer cells as well as other cells important for cancer growth. In laboratory studies, MORAb-004 can decrease the growth of some cancers, such as melanoma. In this study, researchers are assessing the safety and effectiveness of MORAb-004 in patients with metastatic melanoma that has continued to grow despite at least one prior regimen of therapy.
Investigator
D'Angelo, Sandra, MD
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have metastatic melanoma that has continued to grow despite at least one prior regimen of chemotherapy.
- At least 3 weeks must have passed since completion of prior treatment and entry into the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Richard D. Carvajal at 646-888-4164.
Disease(s)
Advanced Cancer
Melanoma
